<DOC>
	<DOCNO>NCT00999713</DOCNO>
	<brief_summary>Acute lung injury ( ALI ) common , life-threatening complication among pediatric leukemia lymphoma hematopoietic stem cell transplant ( HSCT ) recipient . Although child represent relatively small unique patient population , account large proportion death pediatric disease . The long-term goal project improve outcome among patient . Recently , intratracheal administration calfactant result decreased mortality among child ALI include promising result among child cancer follow HSCT . Consequently , primary specific aim study assess effect calfactant intensive care ( PICU ) survival among pediatric leukemia lymphoma HSCT patient ALI . Secondary aim include assessment effect calfactant oxygenation length mechanical ventilation , PICU stay , hospital stay . Calfactant therapy find benefit acute lung injury overall pediatric population improve oxygenation decrease mortality . These finding , conjunction recent subgroup analysis calfactant therapy appear improve outcome immunocompromised child provide rationale assess calfactant therapy patient population . Funding Source - FDA OOPD</brief_summary>
	<brief_title>CALIPSO : Calfactant Acute Lung Injury Pediatric Stem Cell Transplant Oncology Patients</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Calfactant</mesh_term>
	<criteria>1 . Patients must meet criterion acute lung injury Intubated , mechanically ventilate , respiratory failure secondary diffuse , bilateral parenchymal lung disease ( judge chest xray ) . Oxygenation index ( OI ) &gt; 13 , &lt; 37 , two consecutive blood gas separate least one hour within 48 hour initiation mechanical ventilation . Arterial catheter placement Parental inform consent 2 . Patients must diagnosis leukemia/lymphoma undergo active treatment follow HSCT indication . Leukemia/lymphoma define accord National Cancer Institute Surveillance Epidemiology End Results Collaborative Staging Manual include condition define borderline myelodysplastic syndrome . All form HSCT eligible , allogeneic well autologous . 1 . Clinical diagnosis congestive heart failure and/or pulmonary capillary wedge pressure &gt; 15 mmHg , uncorrected congenital heart disease . 2 . Glasgow Coma Score &lt; 8 ( prior respiratory failure ) . 3 . Preexisting limitation care option , ( Do Not Attempt Resuscitation Orders , etc ) . 4 . Patients impend death another disease . 5 . Patients moribund organ failure possible randomization : hypotension unresponsive treatment ( mean BP &lt; 60 &lt; 5th % age ) , persistent cardiac tachyarrhythmia &gt; 150/minute , persistent bradyarrythmia &lt; 50/minute , age appropriate criterion young child , metabolic acidosis &gt; 10 mEq/L 2 hour , persistent arterial oxygen desaturation , PaO2 &lt; 50 SaO2saturation &lt; 80 % , hyperkalemia , serum K+ &gt; 6.5 plus widen QRS complex EKG</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acute Lung Injury</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pediatrics</keyword>
</DOC>